[EN] 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS<br/>[FR] PYRAZOLES 3 SUBSTITUÉS ET UTILISATION EN TANT QU'INHIBITEURS DE DLK
申请人:HOFFMANN LA ROCHE
公开号:WO2014111496A1
公开(公告)日:2014-07-24
The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof.
In compounds of Formula I, the groups R
1
, R
2
, R
3
, R
4
, R
5
, R
6
and R
7
have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
[EN] TRICYCLIC DLK INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE DLK TRICYCLIQUES ET UTILISATIONS ASSOCIÉES
申请人:HOFFMANN LA ROCHE
公开号:WO2016142310A1
公开(公告)日:2016-09-15
The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.